A PYMNTS Company

Amgen-Micromet merger gets HSR early termination

By  |  February 16, 2012

Amgen and Micromet have announced early termination of the Hart-Scott-Rodino waiting period by the FTC. Amgen seeks to acquire Micromet with a tender offer for common stock at $11 per share in cash. Amgen is a biotechnology firm involved in human therapeutics; Micromet is a biopharmaceutical company for antibody-based therapies in cancer treatment.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Source: MarketWatch

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

     

    Related content: New Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions (Janet McDavid & Eric Stock, Hogan Lovells)